Physician profile
Daniel Saade
NPI 1881668580
$3,196.42
in general payments reported to CMS, 2019-2025
19 companies · $729 in 2025
The $729 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $230 · 2021: $172 · 2022: $512 · 2023: $613 · 2024: $763 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $710.92 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $588.11 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $518.88 | 2021-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $281.96 | 2025 | Jornay Pm |
| Tris Pharma INC | $242.42 | 2021-2025 | Dyanavel Xr, Onyda Xr |
| Neos Therapeutics, LP | $198.20 | 2019-2024 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $124.75 | 2019-2023 | Trintellix |
| Novo Nordisk INC | $106.63 | 2022-2025 | Ozempic, Rybelsus |
| Dynavax Technologies Corporation | $98.67 | 2023-2024 | Heplisav-B |
| Glaxosmithkline, LLC. | $80.15 | 2019-2025 | Bexsero, Shingrix, Arexvy |
| Boston Scientific Corporation | $53.52 | 2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Shire North American Group INC | $49.90 | 2019 | |
| Merck Sharp & Dohme LLC | $33.76 | 2022-2024 | Capvaxive, Gardasil 9, Gardasil |
| Abbott Laboratories | $32.81 | 2022-2024 | Freestyle Libre 3 |
| Pfizer INC. | $19.93 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $19.48 | 2023 | Qsymia |
| Lilly USA, LLC | $13.93 | 2023 | Jardiance |
| Cranial Technologies, INC | $11.27 | 2019 | |
| Genentech USA, INC. | $11.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Saade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.